← Back to Calendar

Lazcluze + Rybrevant (lazertinib + amivantamab-vmjw)

Johnson & Johnson · $JNJ
Priority Review Breakthrough Therapy sNDA
PDUFA Date
April 20, 2026
Time Remaining
7 days
Review Type
Priority (6 mo)
92%
Baseline PoA
sNDA/sBLA historical approval rate
Based on FDA historical approval rates by submission type (2015–2025)
Dynamic PoA
Coming soon
xAI Sentiment

Live Company Data NYQ

Updated just now · Data: FMP
Current Price
$238.46 +60.37%
+$89.77 today
Day: $237.91 – $242.26
Market Cap
N/A
Shares out: 2.41B
Float: 2.41B
52-Week Range
$146.12
$251.71
Current price is at 87% of 52-week range
Avg Volume
8.70M
Beta
0.33
vs. S&P 500
Sector
Healthcare
Drug Manufacturers - General
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $JNJ catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

EGFR-mutated NSCLC — first-line treatment

Key Notes

First-line combination for EGFR-mutated non-small cell lung cancer. MARIPOSA trial data.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar